As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
29 Analysts have issued a BioNTech SE - ADR forecast:
29 Analysts have issued a BioNTech SE - ADR forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 3,656 3,656 |
4%
4%
|
|
| Gross Profit | 3,130 3,130 |
1%
1%
|
|
| EBITDA | -510 -510 |
22%
22%
|
|
| EBIT (Operating Income) EBIT | -954 -954 |
6%
6%
|
|
| Net Profit | -663 -663 |
22%
22%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.
| Head office | Germany |
| CEO | Ugur Sahin |
| Employees | 6,772 |
| Founded | 2008 |
| Website | www.biontech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


